Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study

作者：Ningning Zhang, Kaipeng Liu, Yuexi Yu, Kai Yuan, Haipeng Yu, Jean‐Charles Nault, Claudia Campani, Lorraine Blaise, Sara Mouri, Eléonore Spitzer, Yawei Du, Shuwen Zhang, Wenwen Zhu, Yu Hao, Tian Liu, Xuanchen Liu, Ming Luo, Huiru Liu, Yiyan Zhang, Yiming Huo, Feng Duan, Manon Allaire, Wei Lü, Jihui Hao · 发表于：Hepatology International · 年份：2025 · DOI：10.1007/s12072-025-10895-3 · 被引用次数：6 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies、Organ Transplantation Techniques and Outcomes